SARS-CoV-2 is the agent responsible for COVID-19. The infection can be dived into three
phases: mild infection, the pulmonary phase and the inflammatory phase. Treatment options
for the pulmonary phase include: Hydroxychloroquine, Remdesivir, Lopinavir/Ritonavir. The
inflammatory phase includes therapeutic options like Tocilizumab, Anakinra, Baricitinib,
Eculizumab, Emapalumab and Heparin. Human clinical trials are starting to show some
results, in some cases like that of Remdesivir and corticosteroids these are controversial …